NTLA
HEALTHCAREIntellia Therapeutics Inc
AI Insight
What's Moving NTLA Today?
No stock-specific AI insight has been generated for NTLA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.95$28.25
$15.25
Fundamentals
Market Cap$2.2B
P/E Ratio—
EPS$-3.52
Dividend Yield—
Dividend / Share—
ROE-56.3%
Profit Margin—
Debt / Equity—
Trading
Volume4.9M
Avg Volume (10D)—
Shares Outstanding139.7M
NTLA News
29 articles- Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA FilingSimply Wall Street·Jun 21, 2026
- Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?The Motley Fool·Jun 20, 2026
- This Stock Is Up 58% This Year. Is It too Late to Buy?The Motley Fool·Jun 17, 2026
- NTLA Posts Strong Additional Phase III Data From HAE Study, Stock UpYahoo Finance·Jun 16, 2026
- Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?Yahoo Finance·Jun 16, 2026
- Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z ResultsYahoo Finance·Jun 16, 2026
- Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?Yahoo Finance·Jun 15, 2026
- Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling DisorderYahoo Finance·Jun 15, 2026
- Exploring 3 High Growth Tech Stocks in US MarketYahoo Finance·Jun 15, 2026
- Why Is NTLA Stock Jumping 5% Premarket Today?Stocktwits·Jun 15, 2026
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaGlobeNewswire Inc.·Jun 13, 2026
- Exploring High Growth Tech Stocks In The US MarketYahoo Finance·Jun 11, 2026
- Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Jun 10, 2026
- A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity RaiseSimply Wall Street·Jun 9, 2026
- Exploring 3 High Growth Tech Stocks in the US MarketYahoo Finance·Jun 9, 2026
- Lonvo-z Phase 3 Allergy Congress Data Might Change The Case For Investing In Intellia Therapeutics (NTLA)Simply Wall Street·Jun 7, 2026
- NTLA: Phase 3 HAE Progress And FDA Momentum Will Drive Future UpsideSimply Wall Street·Jun 7, 2026
- Intellia Therapeutics, Inc. Trade Ideas — XETR:38ITradingView·Jun 6, 2026
- Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering DilutionYahoo Finance·Jun 6, 2026
- Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study UpdateYahoo Finance·Jun 5, 2026
- High Growth Tech Stocks To Watch In US June 2026Yahoo Finance·Jun 3, 2026
- A Look At Intellia Therapeutics (NTLA) Valuation As Phase 3 HAELO Gene Editing Data ApproachesSimply Wall Street·Jun 2, 2026
- Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026Yahoo Finance·Jun 1, 2026
- Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold LiftSimply Wall Street·May 29, 2026
- ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?Yahoo Finance·May 27, 2026
- High Growth US Tech Stocks To Watch In May 2026Yahoo Finance·May 27, 2026
- Intellia Therapeutics stock (US45826J1051): gene-editing pipeline update keeps investors focused onAD HOC NEWS·May 17, 2026
- Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability TimelineSimply Wall Street·May 13, 2026
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
All 29 articles loaded
Price Data
Open$15.43
Previous Close$15.25
Day High$15.93
Day Low$15.06
52 Week High$28.25
52 Week Low$7.95
52-Week Range
$7.95$28.25
$15.25
Fundamentals
Market Cap$2.2B
P/E Ratio—
EPS$-3.52
Dividend Yield—
Dividend / Share—
ROE-56.3%
Profit Margin—
Debt / Equity—
Trading
Volume4.9M
Avg Volume (10D)—
Shares Outstanding139.7M
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—